Literature DB >> 32015976

The evolving treatment paradigm for BRAF V600 mutant colorectal cancer.

Jeremy D Kratz1, Dustin A Deming1,2,3.   

Abstract

Entities:  

Year:  2019        PMID: 32015976      PMCID: PMC6976492          DOI: 10.21037/atm.2019.12.61

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  20 in total

1.  Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Axel Grothey; Rona Yaeger; Eric Van Cutsem; Jayesh Desai; Takayuki Yoshino; Harpreet Wasan; Fortunato Ciardiello; Fotios Loupakis; Yong Sang Hong; Neeltje Steeghs; Tormod K Guren; Hendrik-Tobias Arkenau; Pilar Garcia-Alfonso; Per Pfeiffer; Sergey Orlov; Sara Lonardi; Elena Elez; Tae-Won Kim; Jan H M Schellens; Christina Guo; Asha Krishnan; Jeroen Dekervel; Van Morris; Aitana Calvo Ferrandiz; L S Tarpgaard; Michael Braun; Ashwin Gollerkeri; Christopher Keir; Kati Maharry; Michael Pickard; Janna Christy-Bittel; Lisa Anderson; Victor Sandor; Josep Tabernero
Journal:  N Engl J Med       Date:  2019-09-30       Impact factor: 91.245

2.  Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Authors:  Jeremy C Jones; Lindsay A Renfro; Humaid O Al-Shamsi; Alexa B Schrock; Andrew Rankin; Ben Y Zhang; Pashtoon M Kasi; Jesse S Voss; Alexis D Leal; James Sun; Jeffrey Ross; Siraj M Ali; Joleen M Hubbard; Benjamin R Kipp; Robert R McWilliams; Scott Kopetz; Robert A Wolff; Axel Grothey
Journal:  J Clin Oncol       Date:  2017-05-09       Impact factor: 44.544

3.  Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Authors:  Ryan B Corcoran; Thierry André; Chloe E Atreya; Jan H M Schellens; Takayuki Yoshino; Johanna C Bendell; Antoine Hollebecque; Autumn J McRee; Salvatore Siena; Gary Middleton; Kei Muro; Michael S Gordon; Josep Tabernero; Rona Yaeger; Peter J O'Dwyer; Yves Humblet; Filip De Vos; A Scott Jung; Jan C Brase; Savina Jaeger; Severine Bettinger; Bijoyesh Mookerjee; Fatima Rangwala; Eric Van Cutsem
Journal:  Cancer Discov       Date:  2018-02-05       Impact factor: 39.397

4.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Authors:  Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; Tobias H Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna C Pavlick; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

Review 5.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Authors:  Filippo Pietrantonio; Fausto Petrelli; Andrea Coinu; Maria Di Bartolomeo; Karen Borgonovo; Claudia Maggi; Mary Cabiddu; Roberto Iacovelli; Ilaria Bossi; Veronica Lonati; Mara Ghilardi; Filippo de Braud; Sandro Barni
Journal:  Eur J Cancer       Date:  2015-02-09       Impact factor: 9.162

6.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Authors:  Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2015-08-31       Impact factor: 41.316

7.  NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Ignacio Garrido-Laguna; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

8.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

9.  Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.

Authors:  Izuma Nakayama; Eiji Shinozaki; Tomohiro Matsushima; Takeru Wakatsuki; Mariko Ogura; Takashi Ichimura; Masato Ozaka; Daisuke Takahari; Mitsukuni Suenaga; Keisho Chin; Nobuyuki Mizunuma; Kensei Yamaguchi
Journal:  BMC Cancer       Date:  2017-01-09       Impact factor: 4.430

10.  Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.

Authors:  Fotios Loupakis; Roberto Moretto; Giuseppe Aprile; Marta Muntoni; Chiara Cremolini; Donatella Iacono; Mariaelena Casagrande; Laura Ferrari; Lisa Salvatore; Marta Schirripa; Daniele Rossini; Giovanna De Maglio; Gianpiero Fasola; Lorenzo Calvetti; Sara Pilotto; Luisa Carbognin; Gabriella Fontanini; Giampaolo Tortora; Alfredo Falcone; Isabella Sperduti; Emilio Bria
Journal:  Br J Cancer       Date:  2015-11-17       Impact factor: 7.640

View more
  1 in total

1.  Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.

Authors:  Qiaoli Yi; Jinwu Peng; Zhijie Xu; Qiuju Liang; Yuan Cai; Bi Peng; Qingchun He; Yuanliang Yan
Journal:  Front Bioeng Biotechnol       Date:  2022-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.